Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00537381 · ClinicalTrials.gov registry record · Phase 2
An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer
A Phase 2 study, sponsored by Centocor.
- Completed
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
NCT00537381 is a Phase 2 study that has completed, run by Centocor. The registered enrollment target is 131 participants.
The verdict
NCT00537381, a Phase 2 study, has completed, sponsored by Centocor.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects of intetumumab when given in combination with docetaxel and prednisone to participants with metastatic (spread of cancer cells from one part of the body to another) hormone-refractory (not responding to treatment) prostate cancer (abnormal tissue that grows and spreads in the body until it kills).
Interventions
- DRUG Placebo
- DRUG Docetaxel
- DRUG Prednisone
- BIOLOGICAL Intetumumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00537381
The ClinicalTrials.gov registry entry for NCT00537381 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centocor, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00537381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00537381 about?
NCT00537381 is a clinical study titled "An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer". The purpose of this study is to assess the effects of intetumumab when given in combination with docetaxel and prednisone to participants with metastatic (spread of cancer cells from one part of the body to another) hormone-refractory (not responding to treatment) prostate cancer (abnormal tissue th...
What is the current status of trial NCT00537381?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2007-05. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00537381?
The interventions under investigation include: Placebo (DRUG), Docetaxel (DRUG), Prednisone (DRUG), Intetumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00537381?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.